# US 2026/0062381 A1 · Methods for synthesis of the tricyclic prostaglandin d2 metabolite methyl ester

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0062381 A1
- Document ID: US20260062381A1
- Status: Published application
- Kind: A1
- Application number: 19/386,009
- Filed: 2025-11-11
- Published: 2026-03-05
- Earliest claimed: 2021-12-03
- Assignees: Purdue Research Foundation
- Applicants: Purdue Research Foundation
- Inventors: Mingji DAI; Hunter SIMS
- Web page: https://patentgrep.com/patent/US20260062381A1

## CPC

- C07C 29/103: {of cyclic ethers}
- C07C 405/0075: {having the side-chains or their analogues or derivatives attached to a condensed ring system}
- C07C 67/14: from carboxylic acid halides
- C07C 201/00: Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07D 307/935: Not further condensed cyclopenta [b] furans or hydrogenated cyclopenta [b] furans
- C07D 493/04: Ortho-condensed systems
- C07C 2601/02: with a three-membered ring
- C07C 2601/10: the ring being unsaturated
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Methods for the synthesis of a tricyclic-prostaglandin D2 metabolite methyl ester or a pharmaceutically acceptable salt thereof.

## Claims

### Claim 1

A method for synthesis of a tricyclic-prostaglandin D2 metabolite (PGDM) methyl ester or a pharmaceutically acceptable salt thereof, the method comprising:
subjecting an iodo-acetal compound to a cyclization reaction with a methyl ester to provide a cyclization product;
reacting the cyclization product with a catalyst and a dialkyldialkoxytitanium reagent under conditions sufficient to produce a cyclopropanol compound;
hydrolyzing the cyclopropanol compound to form a hemi-acetal compound;
reacting the hemi-acetal compound under suitable Wittig reaction or olefination conditions to provide an olefin compound;
subjecting the olefin compound to a carbonylative spirolactonization reaction to produce a compound having an oxaspirolactone moiety, the compound having the structure; and
reacting a molecule having a terminal olefin with the compound having an oxaspirolactone moiety and a Z-selective catalyst under conditions suitable for a Z-selective cross metathesis reaction to produce tricyclic-PGDM methyl ester or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
providing a first compound having a structure of the following formula:
and
converting the first compound to the iodo-acetal compound and deprotecting a silyl ether moiety thereof;
wherein the olefin compound provided by the Wittig reaction or olefination has the structure:

### Claim 3 (depends on 2)

The method of claim 2, wherein deprotecting a silyl ether moiety comprises subjecting the iodo-acetal compound to tetra-n-butylammonium fluoride (TBAF) in the presence of an anhydrous organic solvent.

### Claim 4 (depends on 1)

The method of claim 1, wherein subjecting the iodo-acetal compound to a cyclization reaction comprises:
(a) reacting the iodo-acetal compound and the methyl ester with a radical initiator, a reducing agent, and an alcohol in solution to produce the cyclization product; or
(b) reacting the iodo-acetal compound and the methyl ester with a metal-based reducing agent, a chelating agent, an alcohol, and a dehydrogenation catalyst.

### Claim 5 (depends on 4)

The method of claim 4, wherein the radical initiator of (a) is 2,2′-azobis(2-methylpropionitrile) (AIBN), the reducing agent is sodium cyanoborohydride (NaCNBH3), the methyl ester is methyl acrylate, and the alcohol is tert-Butyl alcohol (t-BuOH).

### Claim 6 (depends on 4)

The method of claim 4, wherein the metal-based reducing agent of (b) is nickel(II) chloride ethylene glycol dimethyl ether complex (NiCl2⋅glyme), the chelating agent is neocupoine, the alcohol is methanol, the dehydrogenation catalyst is a zinc oxide nanopowder, and the methyl ester is methyl acrylate.

### Claim 7 (depends on 1)

The method of claim 1, wherein the catalyst is a Grignard reagent and the dialkyldialkoxytitanium reagent is a stoichiometric amount of CTi(OiPr)3 or titanium tetrachloride/tetra n-butyl titanate (TiCl4).

### Claim 8 (depends on 7)

The method of claim 7, wherein the Grignard reagent is selected from the group consisting of: ethyl magnesium bromide, methyl magnesium chloride, and methyl magnesium bromide.

### Claim 9 (depends on 1)

The method of claim 1, further comprising quenching hydrolysis when at or about 5-10% of the deprotected cyclopropanol compound remains.

### Claim 10 (depends on 1)

The method of claim 1, further comprising concentrating the hemi-acetal compound with dichloromethane (DCM).

### Claim 11 (depends on 1)

The method of claim 1, wherein the Wittig reaction or olefination conditions comprise adding the hemi-acetal compound to a reaction solution comprising methyltriphenylphosphonium bromide (CH3PPh3Br) and potassium hexamethyldisilazanide (KHMDS) in THF.

### Claim 12 (depends on 1)

The method of claim 1, further comprising monitoring a reaction solution of the Wittig reaction or olefination using thin-layer chromatography (TLC) and quenching the Wittig reaction or olefination upon detection of a byproduct.

### Claim 13 (depends on 1)

The method of claim 1, wherein subjecting the olein compound to a carbonylative spirolactonization reaction further comprises combining the olefin compound with a solvent, an oxidant, and a palladium catalyst.

### Claim 14 (depends on 13)

The method of claim 13, wherein the solvent is anhydrous benzene or anhydrous THF, the oxidant is 2,3-Dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), and the palladium catalyst is palladium(II) acetate (Pd(OAc)2) or palladium(II) trifluoroacetate (Pd(TFA)2).

### Claim 15 (depends on 1)

The method of claim 1, wherein the Z-selective catalyst is Ru-Z-Mes or Ru-Z-DIPP.

### Claim 16 (depends on 1)

The method of claim 1, wherein the molecule having a terminal olefin is methyl 3-butenoate.

### Claim 17

A method for synthesis of a tricyclic-prostaglandin D2 metabolite (PGDM) methyl ester or a pharmaceutically acceptable salt thereof, the method comprising:
providing a first compound having a structure of the following formula:
converting the first compound to the iodo-acetal compound and deprotecting a silyl ether moiety thereof, wherein the iodo-acetal compound has a structure of the following formula:
reacting the iodo-acetal compound and the methyl ester with a nickel(II) chloride ethylene glycol dimethyl ether complex (NiCl2⋅glyme), neocupoine, methanol, and zinc oxide nanopowder to provide a cyclization product;
reacting the cyclization product with ethyl magnesium bromide and a stoichiometric amount of CTi(OiPr)3 under conditions sufficient to produce a cyclopropanol compound, followed by deprotecting a silyl ether of the cyclopropanol compound;
hydrolyzing the deprotected cyclopropanol compound to form a hemi-acetal compound having a structure of the following formula:
reacting the hemi-acetal compound under suitable Wittig reaction or olefination conditions to provide an olefin compound, wherein the hemi-acetal compound is combined in a reaction solution with methyltriphenylphosphonium bromide (CH3PPh3Br), potassium hexamethyldisilazanide (KHMDS), and THF;
subjecting the olefin compound to a carbonylative spirolactonization reaction to produce a compound having an oxaspirolactone moiety, the compound having a structure of the following formula:
and
reacting a molecule having a terminal olefin with the compound having an oxaspirolactone moiety and Ru-Z-Mes or Ru-Z-DIPP under conditions suitable for a Z-selective cross metathesis reaction to produce tricyclic-PGDM methyl ester or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 17)

The method of claim 17, further comprising quenching hydrolysis when at or about 5-10% of the deprotected cyclopropanol compound remains.

### Claim 19 (depends on 1)

A tricyclic-prostaglandin D2 metabolite (PGDM) methyl ester or a pharmaceutically acceptable salt thereof produced by the method of claim 1.
